Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial

Journal of Clinical Psychiatry

Volumn 64, Issue 4, 2003, Pages 459-465

  Müller Vahl, Kirsten R ^a   Schneider, Udo ^a   Prevedel, Heidrun ^a   Theloe, Karen ^a   Kolbe, Hans ^a   Daldrup, Thomas ^b   Emrich, Hinderk M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLONAZEPAM; DRONABINOL; NEUROLEPTIC AGENT; PIMOZIDE; PLACEBO; RESERPINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; SIDE EFFECT; SYMPTOMATOLOGY; TIC; TREATMENT OUTCOME; VERTIGO; VIDEOTAPE;

EID: 0038710735     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0417     Document Type: Article

References (32)

1. Singer HS. Current issues in Tourette syndrome. Mov Disord 2000; 15: 1051-1063
2. Robertson MM. Tourette syndrome, associated conditions and the complexities of treatment. Brain 2000;123:425-462
3. Sandyk R, Awerbuch G, Marijuana and Tourette's syndrome. J Clin Psychopharmacol 1988;8:444-445
4. Hemming M, Yellowlees PM. Effective treatment of Tourette's syndrome with marijuana. J Psychopharmacol 1993;7:389-391
5. Müller-Vahl KR, Kolbe H, Schneider U, et al. Cannabinoids: possible role in pathophysiology of Gilles de la Tourette-syndrome. Acta Psychiatr Scand 1998;98:502-506
6. Müller-Vahl KR, Schneider U, Kolbe H, et al. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 1999;156: 495
7. Müller-Vahl KR, Koblenz A, Jöbges M, et al. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry 2001;34:19-24
8. 9-tetrahydrocannabinol (THC). Pharmacopsychiatry 2002;35:57-61
9. Leckman JF, Towbin KE, Ort SI, et al. Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun RD, Leckman JF, eds. Tourette's Syndrome and Tic Disorders. New York, NY: John Wiley & Sons; 1988: 55-78
10. Shapiro AK, Shapiro ES, Young JG, et al. Signs, symptoms, and clinical course. In: Shapiro AK, Shapiro ES, Young JG, et al, eds. Gilles de la Tourette Syndrome. 2nd ed. New York, NY: Raven Press: 1988:127-193
11. Harcherik DF, Leckman JF, Detlor J, et al. A new instrument for clinical studies of Tourette's syndrome. Am J Acad Child Psychiatry 1984;23: 153-160
12. Goetz CG, Tanner CM, Wilson RS, et al. A rating scale for Gilles de la Tourette's syndrome: description, reliability, and validity data. Neurology 1987;37:1542-1544
13. Singer HS, Wendtlandt JT. Neurochemistry and synaptic neurotransmission in Tourette syndrome. Adv Neurol 2001;85:163-178
14. Devane WA, Dysarz FA III, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-613
15. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258: 1946-1949
16. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997;388:773-778
17. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990;87:1932-1936
18. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997;77: 299-318
19. Di Marzo V, Hill MP, Bisogno T, et al. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 2000;14:1432-1438
20. Giuffrida A, Parsons LH, Kerr TM, et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neurosci 1999; 2:358-363
21. Pertwee RG, Wickens AP. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 1991;30:237-244
22. Maneuf YP, Nash JE, Crossman AR, et al. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 1996;308:161-164
23. Auclair N, Otani S, Soubrie P, et al. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol 2000;83:3287-3293
24. Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 2001; 85:468-471
25. Pertwee RG, Greentree SG, Swift PA. Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 1988;27:1265-1270
26. Moss DE, McMaster SB, Rogers J. Tetrahydrocannabinol potentiates reserpine-induced hypokinesia. Pharmacol Biochem Behav 1981;15: 779-783
27. Navarro M, Fernandez-Ruiz JJ, De Miguel R, et al. Motor disturbances induced by an acute dose of delta 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations. Pharmacol Biochem Behav 1993;45:291-298
28. Pryor GT, Larsen FF, Husain S, et al. Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats. Pharmacol Biochem Behav 1978;8:295-318
29. Richter A, Loscher W. (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. Eur J Pharmacol 1994;264:371-377
30. Zimmer A, Zimmer AM, Hohmann AG, et al. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 1999;96:5780-5785
31. Müller-Vahl KR, Kolbe H, Schneider U, et al. Indications for cannabis and THC: movement disorders. In: Grotenhermen F, Russo E, eds. Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potentials. New York, NY: Haworth Press; 2002:205-214
32. Stern E, Silbersweig DA, Chee KY, et al. A functional neuroanatomy of tics in Tourette syndrome. Arch Gen Psychiatry 2000;57:741-748